Antihyperlipidemic effect of Aronia melanocarpa fruit juice in rats fed a high-cholesterol diet

Antihyperlipidemic effect of Aronia melanocarpa fruit juice in rats fed a high-cholesterol diet
复制标题

DOI:
10.1007/s11130-006-0036-2
复制
发表时间:
2007-03-01
影响因子:
4
通讯作者:
Belcheva, A.
Belcheva, A.
中科院分区:
农林科学2区
文献类型:
--
作者:
Valcheva-Kuzmanova, S.;Kuzmanov, K.;Belcheva, A.

文献摘要

被引文献

相似文献

黑果腺肋花楸果汁(AMFJ)中含有丰富的酚类物质(709.3mg没食子酸当量/100 ml果汁)。花色苷(106.8mg花青素-3-葡萄糖苷当量/100 ml果汁)是主要的黄酮类化合物组。本研究的目的是评估AMFJ对饮食诱导的高脂血症大鼠的血脂和脂蛋白谱以及肝脏和主动脉组织病理学的影响。以5、10和20 ml/kg体重的剂量对喂食标准饮食(SD)或含4%胆固醇饮食(4% ChD)的大鼠灌胃给予AMFJ 30天。4%ChD引起血浆总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)显著升高。AMFJ对SD大鼠血脂无明显影响,对4%ChD大鼠TC、LDL-C、TG升高有明显抑制作用。高密度脂蛋白胆固醇(HDL-C)水平没有显着影响,无论是由4%ChD或AMFJ。无论是胆固醇喂养,也AMFJ治疗诱导大鼠肝脏和主动脉的任何组织病理学变化。总之,AMFJ在高脂血症大鼠中显示出抗高血脂作用,并且可能在降低心血管风险因素方面具有价值。
Aronia melanocrpa fruit juice (AMFJ) used in our experiment was very rich in phenolic substances (709.3 mg gallic acid equivalents/100 ml juice). Anthocyanins (106.8 mg cyanidin-3-glucoside equivalents/100 ml juice) were the main flavonoid group. The aim of this study was to assess the influence of AMFJ on plasma lipids and lipoprotein profile, and histopathology of liver and aorta in rats with dietary-induced hyperlipidemia. AMFJ was administered by gavage for 30 days at doses of 5, 10 and 20 ml/kg body weight to rats fed a standard diet (SD) or a 4% cholesterol-containing diet (4% ChD). The 4% ChD caused a significant elevation of plasma total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG). AMFJ did not significantly influence plasma lipids in rats fed the SD and significantly hindered the elevation of plasma TC, LDL-C and TG in rats fed the 4% ChD. High-density lipoprotein cholesterol (HDL-C) levels were not significantly influenced either by the 4% ChD or by AMFJ. Neither the cholesterol feeding, nor AMFJ treatment induced any histopathological changes in rat liver and aorta. In conclusion, AMFJ showed an antihyperlipidemic effect in rats with hyperlipidemia and could be valuable in reducing this factor of cardiovascular risk.